Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.
Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate. J Assoc Physicians India. 2018 Dec;66(12):55-57 Authors: Kalra S, Sahay R Abstract This brief communication describes evidence which proves the beneficial effects of fenofibrate on the retinal vasculature in type 2 diabetes, acting via both lipid lowering and non-lipid lowering mechanisms. It discusses data from FIELD and other trials to support the use of fenofibrate as a secondary preventive therapy for diabetic retinopathy. These data contrast with the lack of retinal benefit shown in major cardiovascular outcome trials of other blood pressure lowering and glucose lowering agents such as empagliflozin, liraglutide, perindopril + indapamide, and ramipril. PMID: 31313550 [PubMed - in process]
Authors: Al-Rawahi A PMID: 32489679 [PubMed]
Authors: Yahaya TO, Ufuoma SB Abstract Single gene mutations have been implicated in the pathogenesis of a form of diabetes mellitus (DM) known as the maturity-onset diabetes of the young (MODY). However, there are diverse opinions on the suspect genes and pathophysiology, necessitating the need to review and communicate the genes to raise public awareness. We used the Google search engine to retrieve relevant information from reputable sources such as PubMed and Google Scholar. We identified 14 classified MODY genes as well as three new and unclassified genes linked with MODY. These genes are fundamentally embedde...
Publication date: Available online 3 June 2020Source: Pharmacological ResearchAuthor(s): Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Shahla Rezaei, Fatemeh Jafari, Kamran Hesami, Mehdi Abedi, Mohammad Jalali, Pedram Keshavarzi, Saeed Shahabi, Ali Asghar Kolahi, Kristin Carson-Chahhoud, Amirhossein Sahebkar, Saeid Safiri
Cardiovascular disease (CVD) is a major contributor to the morbidity and mortality associated with type 2 diabetes mellitus (T2DM). With T2DM growing in pandemic proportions, there will be profound healthcare implications of CVD in person with diabetes. The ideal drugs to improve outcomes in T2DM are those having antiglycemic efficacy in addition to cardiovascular (CV) safety, which has to be determined in appropriately designed CV outcome trials as mandated by regulatory agencies. Available evidence is largely supportive of metformin’s CV safety and potential CVD risk reduction effects, whereas sulfonylureas are eit...
CONCLUSION: This study demonstrates the importance of psychosocial factors in addition to physiological variables in the development of depressive symptoms and incident MDD in people with type 2 diabetes. Stressful life events, depressive symptoms and diabetes-related distress all play a significant role which has implications for practice. A more holistic approach to care, which recognises the interplay of these psychosocial factors, may help to mitigate their impact on diabetes self-management as well as MDD, thus early screening and treatment for symptoms is recommended. PMID: 32484148 [PubMed - in process]
TYPE 2 diabetes directly affects a person's blood sugar levels therefore understanding your levels is extremely crucial. What is equally crucial is finding ways to lower these levels and according to studies, taking this supplement could help. What is it?
BACKGROUND: Diabetes is associated with increased fracture risk but we do not know what affects this risk. We investigated the risk of hip and non-vertebral fractures in diabetes and whether this risk was affected by age, gender, body mass index, diabetes ...
Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2 Interventions: Other: High Carbohydrate (glycogen loading); Other: Low carbohydrate (No Glycogen Loading) Sponsor: University of Virginia Not yet recruiting